FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387331471> ?p ?o ?g. }

• W4387331471 abstract "Various approaches have been developed to enhance the solubility or dissolution rate for the delivery of poorly water-soluble molecules. In this work, guided by an in silico solubility sensitivity analysis for oral absorption, a comparative assessment of the biopharmaceutical performance of a jet-milled free base, a tosylate salt, and a 50:50 (w/w) amorphous solid dispersion (ASD) with hydroxypropyl methylcellulose acetate succinate (HPMCAS) of a weak base drug candidate, GDC-3280, was conducted. Successful particle size reduction without amorphization or form change was confirmed for the jet-milled free base. The potential of solubility enhancement and desupersaturation risk were identified for tosylate salt and ASD formulation by measurements of tosylate salt solubility product constant (Ksp) and amorphous solubility of GDC-3280. In vitro dissolution testing demonstrated dissolution rate improvement for the jet-milled free base when compared with the unmilled free base and confirmed solubility enhancement followed by desupersaturation for GDC-3280 tosylate salt and ASD formulation. A crystallization inhibitor, hydroxypropyl methylcellulose (HPMC), was found to slow down the desupersaturation of tosylate salt solution, providing general insights for the development of pharmaceutical salts with disproportionation risks. Finally, a pharmacokinetic study in dogs showed that the in vivo exposure increased by 1.7- to 2-fold for the tosylate salt and ASD formulation compared with the jet-milled free base, consistent with the in silico solubility sensitivity analysis for the fraction of drug absorbed. Overall, this work provides insights into the evaluation of multiple formulation approaches for enhancing the biopharmaceutical performance of poorly water-soluble drugs." @default.
• W4387331471 created "2023-10-05" @default.
• W4387331471 creator A5000839977 @default.
• W4387331471 creator A5003656736 @default.
• W4387331471 creator A5007072237 @default.
• W4387331471 creator A5010542907 @default.
• W4387331471 creator A5011351323 @default.
• W4387331471 creator A5019065325 @default.
• W4387331471 creator A5038856276 @default.
• W4387331471 creator A5058330415 @default.
• W4387331471 date "2023-10-04" @default.
• W4387331471 modified "2023-10-06" @default.
• W4387331471 title "Comparative Evaluation of Particle Size Reduction, Salt Formation, and Amorphous Formulation on the Biopharmaceutical Performance of a Weak Base Drug Candidate" @default.
• W4387331471 cites W1895149194 @default.
• W4387331471 cites W1972337320 @default.
• W4387331471 cites W1976544366 @default.
• W4387331471 cites W1978823817 @default.
• W4387331471 cites W1985473845 @default.
• W4387331471 cites W1988500533 @default.
• W4387331471 cites W1998891839 @default.
• W4387331471 cites W2001533174 @default.
• W4387331471 cites W2015769892 @default.
• W4387331471 cites W2015983805 @default.
• W4387331471 cites W2030951340 @default.
• W4387331471 cites W2032268755 @default.
• W4387331471 cites W2036630386 @default.
• W4387331471 cites W2038677143 @default.
• W4387331471 cites W2041517295 @default.
• W4387331471 cites W2052280371 @default.
• W4387331471 cites W2057584545 @default.
• W4387331471 cites W2066964643 @default.
• W4387331471 cites W2082157393 @default.
• W4387331471 cites W2089407496 @default.
• W4387331471 cites W2103059913 @default.
• W4387331471 cites W2107831206 @default.
• W4387331471 cites W2138252023 @default.
• W4387331471 cites W2183570525 @default.
• W4387331471 cites W2213042592 @default.
• W4387331471 cites W2225983686 @default.
• W4387331471 cites W2320607110 @default.
• W4387331471 cites W2328474694 @default.
• W4387331471 cites W2331134781 @default.
• W4387331471 cites W2332251533 @default.
• W4387331471 cites W2335512730 @default.
• W4387331471 cites W2344606181 @default.
• W4387331471 cites W2792812132 @default.
• W4387331471 cites W2886419664 @default.
• W4387331471 cites W2952528349 @default.
• W4387331471 cites W3011601004 @default.
• W4387331471 cites W3036803938 @default.
• W4387331471 cites W3104877661 @default.
• W4387331471 cites W3157669913 @default.
• W4387331471 cites W3159811981 @default.
• W4387331471 cites W3173325663 @default.
• W4387331471 cites W3175639691 @default.
• W4387331471 cites W3196383959 @default.
• W4387331471 cites W4286268023 @default.
• W4387331471 cites W4362507090 @default.
• W4387331471 doi "https://doi.org/10.1021/acs.molpharmaceut.3c00727" @default.
• W4387331471 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37792707" @default.
• W4387331471 hasPublicationYear "2023" @default.
• W4387331471 type Work @default.
• W4387331471 citedByCount "0" @default.
• W4387331471 crossrefType "journal-article" @default.
• W4387331471 hasAuthorship W4387331471A5000839977 @default.
• W4387331471 hasAuthorship W4387331471A5003656736 @default.
• W4387331471 hasAuthorship W4387331471A5007072237 @default.
• W4387331471 hasAuthorship W4387331471A5010542907 @default.
• W4387331471 hasAuthorship W4387331471A5011351323 @default.
• W4387331471 hasAuthorship W4387331471A5019065325 @default.
• W4387331471 hasAuthorship W4387331471A5038856276 @default.
• W4387331471 hasAuthorship W4387331471A5058330415 @default.
• W4387331471 hasConcept C127413603 @default.
• W4387331471 hasConcept C147789679 @default.
• W4387331471 hasConcept C155574463 @default.
• W4387331471 hasConcept C178790620 @default.
• W4387331471 hasConcept C180518818 @default.
• W4387331471 hasConcept C185592680 @default.
• W4387331471 hasConcept C187530423 @default.
• W4387331471 hasConcept C192562407 @default.
• W4387331471 hasConcept C203036418 @default.
• W4387331471 hasConcept C2781047461 @default.
• W4387331471 hasConcept C42360764 @default.
• W4387331471 hasConcept C43617362 @default.
• W4387331471 hasConcept C54355233 @default.
• W4387331471 hasConcept C56052488 @default.
• W4387331471 hasConcept C86803240 @default.
• W4387331471 hasConcept C88380143 @default.
• W4387331471 hasConceptScore W4387331471C127413603 @default.
• W4387331471 hasConceptScore W4387331471C147789679 @default.
• W4387331471 hasConceptScore W4387331471C155574463 @default.
• W4387331471 hasConceptScore W4387331471C178790620 @default.
• W4387331471 hasConceptScore W4387331471C180518818 @default.
• W4387331471 hasConceptScore W4387331471C185592680 @default.
• W4387331471 hasConceptScore W4387331471C187530423 @default.
• W4387331471 hasConceptScore W4387331471C192562407 @default.
• W4387331471 hasConceptScore W4387331471C203036418 @default.
• W4387331471 hasConceptScore W4387331471C2781047461 @default.
• W4387331471 hasConceptScore W4387331471C42360764 @default.
• W4387331471 hasConceptScore W4387331471C43617362 @default.

• next